The clinician's expectations from the use of positron emission tomography/computed tomography scanning in untreated and treated head and neck cancer patients

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 16, Issue 2, 2008, Pages 127-134

  Fleming Jr , Alfred J ^a   Johansen, Michael E ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Head and neck cancer; PET CT; Staging; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE;

BIOPSY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; METASTASIS; MOUTH CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY;

HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 40449116073     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e3282f4939a     Document Type: Review

References (41)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8-31.
2. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41:1369-1379.
3. Branstetter BFt, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 2005; 235:580-586.
4. 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol 2006; 11:286-296.
5. 18F-FDG PET/CT in head and neck tumours. Br J Cancer 2005; 92:1046-1050.
6. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188:487-490.
7. Fleming A Jr, Smith S Jr, Agrawal A, Schuller D. Accuracy of various SUV levels in PET/CT of the head and neck. Columbus: Ohio State University; 2006.
8. 18F]-2-fluorodeoxyglucose- positron emission/-computerized tomography for head and neck tumors. Laryngoscope 2005; 115:1186-1190.
9. Ha PK, Hdeib A, Goldenberg D, et al. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006; 132:12-16.
10. Fleming AJ Jr, Smith SP Jr, Paul CM, et al. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007; 117:1173-1179. This retrospective study evaluated PET/CT use in previously untreated HNC patients, with a relatively large number of patients.
11. Veit-Haibach P, Luczak C, Wanke I, et al. TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging 2007; 34:1953-1962.
12. Gordin A, Golz A, Keidar Z, et al. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care. Otolaryngol Head Neck Surg 2007; 137:130-137. Prospective study of PET/CT use in HNC patients.
13. Connell CA, Corry J, Milner A, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck 2007; 29:979-985. This was a prospective study of PET/CT use in HNC patients.
14. Schwartz DL, Ford E, Rajendran J, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 61:129-136.
15. 18F-FDG PET/CT to improve the accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma. Head Neck 2007; 29:203-210.
16. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006; 47:755-762.
17. Wartski M, Le Stanc E, Gontier E, et al. In search of an unknown primary tumour presenting with cervical metastases: performance of hybrid FDG-PET-CT. Nucl Med Commun 2007; 28:365-371. In this retrospective study a relatively large number of patients with HNC of unknown primary were studied with PET/CT and CT alone.
18. Waltonen J, Ozer E, Schuller D, Agrawal A. Diagnosis of unknown primary tumors: changes in the 21st century. Columbus: Ohio State University; 2007.
19. Haas I, Hoffmann TK, Engers R, Ganzer U. Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). Eur Arch Otorhinolaryngol 2002; 259:325-333.
20. Schoder H, Yeung HW, Gonen M, et al. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004; 231:65-72.
21. Wang D, Schultz CJ, Jursinic PA, et al. Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 2006; 65:143-151.
22. 18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002; 20:1398-1404.
23. 18F]fluoro-2-deoxy-D-glucose.[see comment]. Int J Radiat Oncol Biol Phys 2004; 59:1295-1300.
24. Halfpenny W, Hain SF, Biassoni L, et al. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002; 86:512-516.
25. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer. J Nucl Med 1997; 38:1907-1911.
26. 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med 2007; 48:752-757.
27. Kim SY, Roh JL, Kim JS, et al. Utility of FDG PET in patients with squamous cell carcinomas of the oral cavity. Eur J Surg Oncol 2008; 34:208-215.
28. Podoloff DA, Advani RH, Allred C, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007; 5 (Suppl 1):S1-S22.
29. Andrade RS, Heron DE, Degirmenci B, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 2006; 65:1315-1322.
30. Fakhry N, Lussato D, Jacob T, et al. Comparison between PET and PET/CT in recurrent head and neck cancer and clinical implications. Eur Arch Otorhinolaryngol 2007; 264:531-538.
31. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945-1952.
32. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937-1944.
33. Oliver C, Muthukrishnan A, Mountz J, et al. Interpretability of PET/CT imaging in head and neck cancer patients following composite mandibular resection and osteocutaneous free flap reconstruction. Head Neck 2008; 30:187-193.
34. Shintani SA, Foote RL, Lowe VJ, et al. Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 66:S426.
35. Gil Z, Even-Sapir E, Margalit N, Fliss DM. Integrated PET/CT system for staging and surveillance of skull base tumors. Head Neck 2007; 29:537-545.
36. Gourin CG, Williams HT, Seabolt WN, et al. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. Laryngoscope 2006; 116:705-710.
37. Yao M, Luo P, Hoffman HT, et al. Pathology and FDG PET correlation of residual lymph nodes in head and neck cancer after radiation treatment. Am J Clin Oncol 2007; 30:264-270.
38. Nayak JV, Walvekar RR, Andrade RS, et al. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope 2007; [Epub ahead of print].
39. Ryan WR, Fee WE Jr, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005; 115:645-650.
40. Lonneux M, Lawson G, Ide C, et al. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000; 110:1493-1497.
41. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2005; 63:991-999.